Research analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Price Performance
Cumberland Pharmaceuticals stock opened at $1.74 on Wednesday. Cumberland Pharmaceuticals has a fifty-two week low of $1.55 and a fifty-two week high of $2.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.31 and a current ratio of 1.70. The company has a market capitalization of $25.14 million, a P/E ratio of -6.21 and a beta of 0.34. The stock has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.20.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) last posted its earnings results on Tuesday, March 7th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 9.97% and a positive return on equity of 4.76%. The firm had revenue of $9.12 million during the quarter.
Institutional Trading of Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex.
- Get a free copy of the StockNews.com research report on Cumberland Pharmaceuticals (CPIX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.